MX2023003618A - Formas cristalinas de un compuesto farmaceutico. - Google Patents

Formas cristalinas de un compuesto farmaceutico.

Info

Publication number
MX2023003618A
MX2023003618A MX2023003618A MX2023003618A MX2023003618A MX 2023003618 A MX2023003618 A MX 2023003618A MX 2023003618 A MX2023003618 A MX 2023003618A MX 2023003618 A MX2023003618 A MX 2023003618A MX 2023003618 A MX2023003618 A MX 2023003618A
Authority
MX
Mexico
Prior art keywords
compound
crystalline form
crystalline forms
pharmaceutical compound
relates
Prior art date
Application number
MX2023003618A
Other languages
English (en)
Spanish (es)
Inventor
Fritz Blatter
Robert Hett
Jennifer Robin
Kyle Landskroner
Original Assignee
Azafaros B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azafaros B V filed Critical Azafaros B V
Publication of MX2023003618A publication Critical patent/MX2023003618A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2023003618A 2020-10-02 2021-10-01 Formas cristalinas de un compuesto farmaceutico. MX2023003618A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20199934.9A EP3978474A1 (en) 2020-10-02 2020-10-02 Crystalline forms of a pharmaceutical compound
PCT/EP2021/077100 WO2022069709A1 (en) 2020-10-02 2021-10-01 Crystalline forms of a pharmaceutical compound

Publications (1)

Publication Number Publication Date
MX2023003618A true MX2023003618A (es) 2023-07-14

Family

ID=72744696

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003618A MX2023003618A (es) 2020-10-02 2021-10-01 Formas cristalinas de un compuesto farmaceutico.

Country Status (19)

Country Link
US (2) US12116344B2 (cg-RX-API-DMAC10.html)
EP (3) EP3978474A1 (cg-RX-API-DMAC10.html)
JP (2) JP7809655B2 (cg-RX-API-DMAC10.html)
KR (2) KR20240056628A (cg-RX-API-DMAC10.html)
CN (1) CN116390910A (cg-RX-API-DMAC10.html)
AU (2) AU2021353055B2 (cg-RX-API-DMAC10.html)
BR (2) BR122022018214A2 (cg-RX-API-DMAC10.html)
CA (1) CA3193939C (cg-RX-API-DMAC10.html)
CL (1) CL2023000943A1 (cg-RX-API-DMAC10.html)
DK (1) DK4114826T3 (cg-RX-API-DMAC10.html)
ES (1) ES2964105T3 (cg-RX-API-DMAC10.html)
FI (1) FI4114826T3 (cg-RX-API-DMAC10.html)
IL (2) IL316634A (cg-RX-API-DMAC10.html)
MA (1) MA58885B1 (cg-RX-API-DMAC10.html)
MX (1) MX2023003618A (cg-RX-API-DMAC10.html)
PE (1) PE20240138A1 (cg-RX-API-DMAC10.html)
TW (1) TWI912383B (cg-RX-API-DMAC10.html)
WO (1) WO2022069709A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202310184B (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3978474A1 (en) * 2020-10-02 2022-04-06 Azafaros B.V. Crystalline forms of a pharmaceutical compound
IL314212A (en) * 2022-01-10 2024-09-01 Azafaros B V Treatment of GM2 gangliosidosis
EP4209215A1 (en) * 2022-01-10 2023-07-12 Azafaros B.V. Treatment of gm2 gangliosidosis
AU2025214578A1 (en) 2024-02-01 2026-08-13 Azafaros B.V. Treatment of gm1 gangliosidosis
EP4595964A1 (en) 2024-02-01 2025-08-06 Azafaros B.V. Treatment of gm1 gangliosidosis
EP4678174A1 (en) * 2024-07-11 2026-01-14 Azafaros B.V. Nizubaglustat for use in the treatment of lysosomal storage disorders
WO2026013261A1 (en) * 2024-07-11 2026-01-15 Azafaros B.V. Nizubaglustat for use in the treatment of lysosomal storage disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2895490T3 (es) 2014-03-27 2022-02-21 Acad Medisch Ct Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa
US20190195897A1 (en) * 2015-06-24 2019-06-27 Universiteit Leiden Glycosylated metabolites
EP3978474A1 (en) * 2020-10-02 2022-04-06 Azafaros B.V. Crystalline forms of a pharmaceutical compound

Also Published As

Publication number Publication date
WO2022069709A1 (en) 2022-04-07
JP7809655B2 (ja) 2026-02-02
AU2021353055B2 (en) 2022-10-06
TWI912383B (zh) 2026-01-21
TW202229236A (zh) 2022-08-01
EP3978474A1 (en) 2022-04-06
AU2022291486A1 (en) 2023-02-02
ES2964105T3 (es) 2024-04-04
FI4114826T3 (fi) 2023-11-21
IL301882B1 (en) 2024-12-01
EP4114826A1 (en) 2023-01-11
CL2023000943A1 (es) 2023-09-29
DK4114826T3 (da) 2023-11-13
PE20240138A1 (es) 2024-01-30
NZ798892A (en) 2023-09-29
IL301882A (en) 2023-06-01
CN116390910A (zh) 2023-07-04
KR20240056628A (ko) 2024-04-30
BR112022018020A2 (pt) 2023-04-18
JP2024054192A (ja) 2024-04-16
IL301882B2 (en) 2025-04-01
BR112022018020B1 (pt) 2023-12-26
CA3193939C (en) 2024-02-20
EP4295847A3 (en) 2024-02-28
US20230391724A1 (en) 2023-12-07
ZA202310184B (en) 2024-01-31
AU2021353055A1 (en) 2022-09-15
KR20230078798A (ko) 2023-06-02
US12116344B2 (en) 2024-10-15
AU2022291486B2 (en) 2024-07-25
US20250059137A1 (en) 2025-02-20
KR102659466B1 (ko) 2024-04-19
US20240287001A9 (en) 2024-08-29
JP2023524169A (ja) 2023-06-08
CA3193939A1 (en) 2022-04-07
IL316634A (en) 2024-12-01
EP4295847A2 (en) 2023-12-27
MA58885B1 (fr) 2023-11-30
EP4114826B1 (en) 2023-08-23
BR122022018214A2 (pt) 2023-05-09

Similar Documents

Publication Publication Date Title
ZA202310184B (en) Crystalline forms of a pharmaceutical compound
MX2022006865A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
MX2021010700A (es) Compuestos utiles en la terapia del vih.
JOP20190193B1 (ar) ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
MX2024013020A (es) Compuestos de heteroarilo para el tratamiento del dolor
PH12021553102A1 (en) Methods of treating fabry disease in patients having renal impairment
MX2021012491A (es) Agentes antiproliferativos para el tratamiento de la hipertensión arterial pulmonar.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
PH12020551117A1 (en) Compositions for preventing or treating uveitis
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2025014320A (es) Compuestos nitrogenados aromaticos, metodos de preparacion y usos medicinales
MX418886B (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses
MX2025002790A (es) Derivados de piperidina 2-sustituidos, metodos de preparacion y usos medicinales de los mismos
MA42301B1 (fr) Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone
MY197442A (en) Novel compounds and their use in the treatment of schistosomiasis
MX390998B (es) Metodo para tratar enfermedades mediante anestesia auricular de los nervios craneales.
TW200639159A (en) Treatment of pain
PH12017502145A1 (en) Composition and uses thereof
MX2022012001A (es) Tratamiento preventivo de la migra?a.
SG10201406846XA (en) Bisphosphonate compounds for treating bone metabolism disorders
WO2023150790A3 (en) Novel and highly selective sars-cov-2 mpro inhibitors
ZA202211253B (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases
EP4620940A3 (en) Synthesis of (+)-cannabinoids and their therapeutic effects
MX2023009620A (es) Metodos terapeuticos.